{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"44","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"Percentage of participants out of total treated alive with disease progression 3 years following registration. Progression-free survival (PFS) was measured from the date of study registration to the date of documented disease progression or death of any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycle 1: Cyclophosphamide 300 mg/m\\^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m\\^2 continuous IV Days 1-3. Doxil 25 mg/m\\^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m\\^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.\n\nCycle 2: Methotrexate 200 mg/m\\^2 over 2 hours on Day 1 and 800 mg/m\\^2 over 22 hours on day 1. Cytarabine 3 Gm/m\\^2 IV twice a day on Days 2 and 3.","id":"OG000","title":"HCVIDDOXIL Regimen"}],"paramType":"NUMBER","populationDescription":"Of the 53 participants, \\*6 participants\\* were not evaluable for response due to either no measurable disease (1) or early departure from study for adverse events (5)","reportingStatus":"POSTED","timeFrame":"From registration to disease progression or death, up to 3 years","title":"3 Year Progression-Free Survival Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}